Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SPHS
CUSIPN/A
Phone858-777-1760
Debt
Debt-to-Equity Ratio1.30
Current Ratio5.90
Quick Ratio5.90
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.25 per share
Price / Book12.36
Profitability
EPS (Most Recent Fiscal Year)($0.40)
Net Income$-8,620,000.00
Net MarginsN/A
Return on Equity-138.96%
Return on Assets-48.63%
Miscellaneous
Employees6
Outstanding Shares30,110,000
Market Cap$93.04
Sophiris Bio (NASDAQ:SPHS) Frequently Asked Questions
What is Sophiris Bio's stock symbol?
Sophiris Bio trades on the NASDAQ under the ticker symbol "SPHS."
How were Sophiris Bio's earnings last quarter?
Sophiris Bio Inc (NASDAQ:SPHS) announced its quarterly earnings results on Monday, May, 14th. The biopharmaceutical company reported ($0.11) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.13) by $0.02. View Sophiris Bio's Earnings History.
What price target have analysts set for SPHS?
2 Wall Street analysts have issued 1-year target prices for Sophiris Bio's stock. Their forecasts range from $4.30 to $8.00. On average, they expect Sophiris Bio's share price to reach $6.15 in the next year. This suggests a possible upside of 99.0% from the stock's current price. View Analyst Ratings for Sophiris Bio.
What is the consensus analysts' recommendation for Sophiris Bio?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sophiris Bio in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Sophiris Bio stock?
Here are some recent quotes from research analysts about Sophiris Bio stock:
- 1. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We maintain our Buy rating but are reducing our price target to $4.30 from $6. The changes to our valuation include: (1) adjustment to base year; (2) adjustment to fully diluted share count; (3) increasing our discount rate from 15% to 20% to account for the increased risk profile of topsalysin, pending information regarding the patient who passed away; and (4) adjusting our projected launch year for topsalysin to 2023 from 2022, also pending information regarding the patient and next steps." (6/25/2018)
- 2. Maxim Group analysts commented, "We note that the P2 study of topsalysin is approaching data in prostate cancer, expected in the coming weeks and in our view represents a significant catalyst for the company. Sophiris’ valuation has steadily risen over the last two months, since early May, we believe on the expectation of a positive outcome. Based on prior data in prostate cancer for topsalysin, demonstrating tumor ablation at 6 months in 9/18 patients, we believe the probability of success in the P2 study (same time, endpoint) favors Sophiris." (6/20/2018)
Who are some of Sophiris Bio's key competitors?
Some companies that are related to Sophiris Bio include Kindred Biosciences (KIN), Ra Pharmaceuticals (RARX), Vital Therapies (VTL), MediciNova (MNOV), Clementia Pharmaceuticals (CMTA), Avid Bioservices (CDMO), BioSpecifics Technologies (BSTC), Paratek Pharmaceuticals (PRTK), Seres Therapeutics (MCRB), Sienna Biopharmaceuticals (SNNA), Achaogen (AKAO), Clearside Biomedical (CLSD), Bellicum Pharmaceuticals (BLCM), Innate Pharma (IPHYF) and Catalyst Pharmaceuticals (CPRX).
Who are Sophiris Bio's key executives?
Sophiris Bio's management team includes the folowing people:
- Mr. Randall E. Woods, Pres, CEO & Director (Age 66)
- Mr. Peter T. Slover CPA, Chief Financial Officer (Age 43)
- Dr. Allison J. Hulme Ph.D., COO, Head of R&D and Director (Age 55)
- Dr. Samuel R. Denmeade M.D., Chief Scientific Officer and Member of the Scientific Advisory Board
- Dr. James Joseph Beesley BSc, DC, Sr. Director of Investor Relations (Age 46)
Has Sophiris Bio been receiving favorable news coverage?
News stories about SPHS stock have trended somewhat positive on Sunday, Accern Sentiment reports. The research firm identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Sophiris Bio earned a daily sentiment score of 0.15 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 46.64 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
How do I buy shares of Sophiris Bio?
Shares of SPHS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sophiris Bio's stock price today?
One share of SPHS stock can currently be purchased for approximately $3.09.
How big of a company is Sophiris Bio?
Sophiris Bio has a market capitalization of $93.04 million. The biopharmaceutical company earns $-8,620,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. Sophiris Bio employs 6 workers across the globe.
How can I contact Sophiris Bio?
Sophiris Bio's mailing address is 1258 PROSPECT STREET, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-777-1760 or via email at [email protected]
MarketBeat Community Rating for Sophiris Bio (NASDAQ SPHS)
MarketBeat's community ratings are surveys of what our community members think about Sophiris Bio and other stocks. Vote "Outperform" if you believe SPHS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPHS will underperform the S&P 500 over the long term. You may vote once every thirty days.
